100 Participants Needed

Neuropeptide Y for High Blood Pressure

(OB-HTN Trial)

CM
MC
Overseen ByMary Childers
Age: 18 - 65
Sex: Any
Trial Phase: Phase < 1
Sponsor: University of Texas Southwestern Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is Neuropeptide Y safe for use in humans?

Neuropeptide Y (NPY) is involved in controlling blood pressure and cardiovascular functions, but its safety in humans is not clearly established. It has direct effects on blood vessels and interacts with other substances that affect blood pressure, but more research is needed to understand its safety profile.12345

How does the drug Neuropeptide Y differ from other treatments for high blood pressure?

Neuropeptide Y (NPY) is unique because it is a peptide that works by modulating the sympathetic nervous system, influencing blood pressure through its vasoconstrictor properties and interaction with other cardiovascular hormones. Unlike traditional blood pressure medications that often target adrenergic receptors, NPY acts independently of adrenergic activation, offering a novel mechanism for blood pressure control.12678

What data supports the effectiveness of the drug Neuropeptide Y for high blood pressure?

Research suggests that Neuropeptide Y (NPY) can directly cause blood vessels to constrict, which might help control blood pressure. It also enhances the effects of other substances that affect blood pressure, indicating it could play a role in managing high blood pressure.14679

Are You a Good Fit for This Trial?

This trial is for adults aged 18-55 who are either healthy, overweight (BMI>30), have high blood pressure, or both. Participants must not have other significant cardiovascular diseases, kidney disease, a history of smoking, or diabetes.

Inclusion Criteria

If you are between the ages of 18 and 55 and have high blood pressure, you may not be eligible if you are not obese, or if your body mass index (BMI) is less than 30.
I am between 18-55, have a BMI over 30, and diagnosed with high blood pressure.
I am 18-55 years old, have a BMI under 30, and my high blood pressure was confirmed by a 24-hour monitor.
See 1 more

Exclusion Criteria

People with diabetes are not allowed in the study.
I have a significant heart condition.
I have kidney disease.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo physiological stress protocols and drug infusions to measure sympathetic nervous system activity and blood flow

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Neuropeptide Y
Trial Overview The study aims to understand how stress affects blood pressure in people with obesity and/or hypertension by measuring nervous system activity and blood flow during stress tests and drug-induced changes in vessel size.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: Obese-hypertensiveExperimental Treatment1 Intervention
Obese adults who are being treated for hypertension
Group II: ObeseExperimental Treatment1 Intervention
Obese adults who are not hypertensive
Group III: HypertensiveExperimental Treatment1 Intervention
Hypertensive adults who are not obese
Group IV: Healthy ControlExperimental Treatment1 Intervention
Healthy age matched controls with no history of cardiovascular disease and normal bodyweight

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Texas Southwestern Medical Center

Lead Sponsor

Trials
1,102
Recruited
1,077,000+

Published Research Related to This Trial

Neuropeptide Y (NPY) is involved in regulating cardiovascular function and blood pressure, acting as a cotransmitter in sympathetic neurons and influencing responses in both the brain and peripheral tissues.
In hypertension, the effects of NPY may change, leading to increased vasoconstriction and potential contributions to the development of high blood pressure, suggesting it could be a target for future research and treatment strategies.
Neuropeptide Y: a possible role in hypertension?Michel, MC., Rascher, W.[2006]
Neuropeptide Y (NPY) has direct vasoconstrictor properties that can affect blood pressure independently of adrenergic activation, indicating its potential role in cardiovascular regulation.
NPY may enhance the effects of other substances that stimulate blood vessels and could influence blood pressure by regulating hormone release related to cardiovascular function.
Cardiovascular effects of neuropeptide Y.Waeber, B., Aubert, JF., Corder, R., et al.[2019]
Patients with pregnancy-induced hypertension (PIH) had significantly higher plasma neuropeptide Y (NPY) levels compared to normal non-pregnant and normal pregnant women, indicating a potential link between elevated NPY and PIH.
After delivery, plasma NPY levels decreased in moderate and severe PIH patients, but levels remained elevated compared to normal non-pregnant women, suggesting that NPY may contribute to the persistence of hypertension even after pregnancy.
[Changes of plasma level of neuropeptide Y in patients with pregnancy induced hypertension].Jin, L., Wang, C.[2006]

Citations

Neuropeptide Y: a possible role in hypertension? [2006]
Cardiovascular effects of neuropeptide Y. [2019]
[Changes of plasma level of neuropeptide Y in patients with pregnancy induced hypertension]. [2006]
Platelet neuropeptide Y in spontaneously hypertensive rats. [2006]
Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. [2019]
Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. [2010]
The therapeutic potential of neuropeptide Y in cardiovascular disease. [2019]
Multiple neuropeptide Y receptors are involved in cardiovascular regulation. Peripheral and central mechanisms. [2019]
The role of neuropeptide Y in cardiovascular regulation. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity